Genomics

Dataset Information

0

Global and targeted microRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence [discovery phase]


ABSTRACT: About 30% of renal cell carcinoma (RCC) patients undergoing nephrectomy experience disease recurrence. This study aimed to profile microRNAs (miRNAs) that are dysregulated in clear cell RCC (ccRCC) tumor tissues and predictive of recurrence. The expression levels of 800 miRNAs were assessed in paired tumor and normal tissues from a discovery cohort of 18 ccRCC patients via the NanoString assay platform. MiRNAs found to be differentially expressed were further examined in a validation set of 205 patients using quantitative real-time PCR. Tumor-normal data from 64 patients in The Cancer Genome Atlas were used for external validation. Results showed 28 miRNAs were consistently dysregulated in tumor tissues. Dichotomized analyses indicated patients with high levels of miR-155-5p and miR-210-3p displayed increased risk of ccRCC recurrence (HR, 2.64; 95% CI, 1.49-4.70; P=0.0009 and HR, 1.8; 95% CI, 1.04-3.12; P=0.036, respectively) and shorter median recurrence-free survival times than patients with low levels (log rank test P<0.01). A risk score was generated based on expression levels of miR-155-5p and miR-210-3p, and the trend test was significant (P for trend=0.005). Pathway analysis revealed target genes regulated by miR-155-5p and miR-210-3p were mainly enriched in inflammation-related pathways. In summary, we identified and validated multiple miRNAs dysregulated in ccRCC tissues. MiR-155-5p and miR-210-3p were predictive of ccRCC recurrence pointing to potential utility as biomarkers and underlying biological mechanisms.

ORGANISM(S): Homo sapiens

PROVIDER: GSE116251 | GEO | 2018/10/04

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2017-08-23 | GSE74174 | GEO
2010-07-22 | E-GEOD-23085 | biostudies-arrayexpress
2010-07-22 | GSE23085 | GEO
2023-05-10 | PXD036109 | Pride
2024-12-11 | PXD041087 | Pride
| EGAS00001005296 | EGA
2021-02-01 | GSE151419 | GEO
2021-02-01 | GSE151423 | GEO
2014-07-17 | E-GEOD-57418 | biostudies-arrayexpress
2018-02-16 | GSE103161 | GEO